vs
Cellyan Biotechnology Co., Ltd（HKPD）与康宝莱（HLF）财务数据对比。点击上方公司名可切换其他公司
康宝莱是美国跨国多层次营销企业，主营膳食补充剂的研发与销售。该公司曾被指控涉嫌金字塔骗局欺诈运营，2016年与美国证监会达成协议后调整了薪酬体系，将经销商奖励与可核实的实际销售额挂钩。此外其部分产品曾被曝出引发急性肝炎的相关问题。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
HKPD
HLF
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
净利润HKPDHLF
| Q4 25 | — | $85.4M | ||
| Q3 25 | — | $43.2M | ||
| Q2 25 | — | $49.3M | ||
| Q1 25 | — | $50.4M | ||
| Q4 24 | — | $177.9M | ||
| Q3 24 | — | $47.4M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | — | $24.3M |
毛利率HKPDHLF
| Q4 25 | — | 77.5% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 78.0% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 77.8% | ||
| Q3 24 | — | 78.3% | ||
| Q2 24 | — | 77.9% | ||
| Q1 24 | — | 77.5% |
营业利润率HKPDHLF
| Q4 25 | — | 7.8% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.7% |
净利率HKPDHLF
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.9% |
每股收益（稀释后）HKPDHLF
| Q4 25 | — | $0.81 | ||
| Q3 25 | — | $0.42 | ||
| Q2 25 | — | $0.48 | ||
| Q1 25 | — | $0.49 | ||
| Q4 24 | — | $1.75 | ||
| Q3 24 | — | $0.46 | ||
| Q2 24 | — | $0.05 | ||
| Q1 24 | — | $0.24 |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
